Arthneeti
Latest: Marksans Pharma Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q3 FY26 (Oct–Dec 2025).All Q3 FY26 results →
MP

Marksans Pharma Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Marksans Pharma Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹321
Market cap₹12.3K Cr
P/E29.5
Updated23 Aug 2026
Read4 min read

The short version

U.S. The company aims to achieve INR 4,000 crores revenue milestone in the next 2-3 years (by FY28 or FY29), with INR 5,000 crores targeted thereafter.

From Marksans Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • U.S. Market:
  • Order book strong at $220 million+, expecting ~20% growth in the upcoming financial year.
  • Growth seen despite geopolitical uncertainties in 2025, with optimism returning post trade deal.
  • New product launches expected to drive revenue; operating leverage visible from Teva facility.
  • Order book revenues (commercialization lag of ~5-6 months) to reflect more in next financial year.
  • U.K. Market:
  • Price erosion stabilizing; seasonal factors and new product filings (~4-5 products/month) expected to support growth.
  • Expecting healthy quarter-on-quarter growth in Q4 FY26.
  • New products have higher margins, expected to improve profitability over 18-24 months.
  • Europe & Canada:
  • Operations recently started; contribution expected over next 3-5 years.
  • Exploring M&As in Europe, with two acquisitions targeted, adding to growth.
  • Overall:
  • Targeting INR 4,000 crores revenue milestone in 2-3 years (FY28/29).

2 more points from Marksans Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Regular capex is around INR 50-60 crores, mainly for optimizations.
  • A new manufacturing plant or block would trigger a larger capex of INR 150-200 crores, subject to order book and demand.
  • Current utilization of the Goa facility is about 50%, so significant hiring occurred there; employee cost is expected to normalize as utilization improves.
  • No immediate trigger to invest in a new block yet.
  • The Teva facility is contributing positively with revenues trending INR 560-600 crores, targeting INR 800 crores, aiding operating leverage.
  • Management is actively exploring acquisitions in Europe and Canada as strategic investments to accelerate growth in these regions.

2 more points from Marksans Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Current order book stands at over $220 million, primarily for the U.S. market.
  • Previous order book figures were around $180-190 million and have grown to $220 million.
  • The $220 million order book is expected to translate into revenue mainly in the next financial year, with a 5-6 month lag from order award to commercialization.
  • The company aims for a $300 million order book in the U.S. by FY28.
  • The order book relates mainly to the U.S., where the company expects strong growth.

2 more points from Marksans Pharma Ltd's call on order book

Create a free account to keep reading this call

Marksans Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹856 Cr, net profit ₹149 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Guj. Themis Bio. (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Marksans Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Marksans Pharma Ltd Q3 FY26 results?

U.S. The company aims to achieve INR 4,000 crores revenue milestone in the next 2-3 years (by FY28 or FY29), with INR 5,000 crores targeted thereafter.

What is Marksans Pharma Ltd share price analysis?

Marksans Pharma Ltd currently shows a neutral. The stock trades at a P/E of 29.4 with a market cap of ₹12,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Marksans Pharma Ltd planning capital expenditure?

Regular capex is around INR 50-60 crores, mainly for optimizations.

Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.